Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bendamustine + Rituximab as Salvage Therapy Before Autologous Stem Cell Transplant in Relapsed/Recurrent DLBCL
jRCTs071210121Phase 2Completed
- Sponsor
- SymBio Pharmaceuticals
- Start
- Jan 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bendamustine and rituximab in diffuse large B-cell lymphoma (DLBCL), sponsored by SymBio Pharmaceuticals. Primary endpoint: Primary: Salvage chemotherapy response rate adjusted for successful HSC collection after 3 cycles. Started Jan 2022; status: completed.
02
Drugs
bendamustinerituximab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on jRCTs071210121.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs071210121.